Union Health Minister Launches Second Phase of Nationwide Bi-Annual MDA Campaign 2024

Union health minister launches second phase of nationwide Bi-annual MDA campaign 2024 to eliminate lymphatic filariasis

Overview

Union minister of state for health & family welfare, Prataprao Ganpatrao Jadhav virtually launched the second phase of the Bi-annual Nationwide Mass Drug Administration (MDA) campaign for lymphatic filariasis elimination, on Saturday.

Target Regions of Campaign

The campaign targets 63 endemic districts across Bihar, Jharkhand, Karnataka, Odisha, Telangana, and Uttar Pradesh and will provide door-to-door administration of preventive medications in endemic areas, advancing India’s goal to eliminate lymphatic filariasis ahead of the global target. Alongside this, the ‘Revised Guideline on Elimination of Lymphatic Filariasis’ and IEC material were unveiled to provide a clear roadmap for elimination efforts.

Attending ministers

State health ministers who joined the event included Banna Gupta (Jharkhand), Mangal Pandey (Bihar), Damodar Rajanarasimha (Telangana), Dr Mukesh Mahaling (Odisha), Jai Pratap Singh (Uttar Pradesh) and Dinesh Gundu Rao (Karnataka).

Statement from Prataprao Jadhav

• In his keynote address, Prataprao Jadhav stated that “Lymphatic filariasis, a mosquito-borne disease is preventable through simple measures, therefore, the Mass Drug Administration (MDA) rounds are crucial in halting its transmission.”
• Jadhav reaffirmed the government's unwavering commitment to public health stating, “Preventive measures such as avoiding mosquito bites and consuming anti-filarial medicines are key to stopping the transmission of lymphatic filariasis, which affects populations across 20 states and union territories in India. This disease not only impacts health and well-being but also leads to lifelong disability, due to lymphedema, affecting families profoundly. To ensure success in the upcoming MDA rounds it is imperative that 90% of all eligible populations consume these medicines.” He stressed on the need to have dedicated efforts to prevent and eliminate lymphatic filariasis in India.

Additional Notes

• Minister also noted that efforts are being made to ensure pucca houses for people living in mud houses that make them more vulnerable to such diseases. 
• He said efforts will also be made to develop a vaccine for lymphatic filariasis. 
• He also highlighted that disability certificates are provided to the people affected with lymphatic filariasis.

MDA Campaign

He launched the MDA campaign by consuming the medicine himself and applauded the dedication and efforts of the line ministries, self-help groups, and other stakeholders for their contribution to the success of the campaign.

For Eliminating Lymphatic Filariasis

• State health ministers spoke about their achievements and efforts in the direction of eliminating lymphatic filariasis since the inception of the elimination of the lymphatic filariasis programme in 2004. 
• They also thanked the Union government for their unwavering support and assured their commitment towards eliminating the disease.

From the Additional Secretary And MD: Health Ministry

• Aradhana Patnaik, additional secretary and MD (NHM), health ministry, stated that lymphatic filariasis is a preventable disease and this MDA campaign is currently being launched in 6 states. 
• As part of the second phase of the MDA campaign on 10th August 2024, 63 districts (38 triple drug & 25 double drug), and 771 blocks across 6 states are conducting the MDA campaign. 
• She stated that the focus this time is not only on the distribution of medicines but to ensure their consumption so that the campaign achieves a success.

Vandana Jain, joint secretary, health ministry emphasised that “Lymphatic filariasis, a mosquito-borne disease is preventable through simple measures, therefore, the Mass Drug Administration (MDA) rounds are crucial in halting its transmission.""

Present Dignitaries 

Dr Atul Goel, director general of health services; Vandana Jain, joint secretary, health ministry; Dr Tanu Jain, director, National Centre for Vector-Borne Diseases and senior officials of the Union health ministry were present on the occasion.

Lymphatic Filariasis

• Lymphatic filariasis (LF) commonly known as elephantiasis (Haatipaon), is a serious debilitating disease transmitted through the bite of a Culex mosquito that breeds in dirty/polluted water. 
• Infection is usually acquired in childhood causing hidden damage to the lymphatic system with visible manifestations (lymphoedema, elephantiasis, and scrotal swelling/hydrocele) which occur later in life and can lead to permanent disability.

About Lymphatic Filariasis

• Lymphatic filariasis (Haatipaon) is a priority disease that is targeted for elimination by 2027. 
• Currently, LF has been reported in 345 districts across 20 states and union territories, with 90% of LF burden contributed by 8 states - Bihar, Chhattisgarh, Jharkhand, Madhya Pradesh, Maharashtra, Odisha, Uttar Pradesh, and West Bengal. 
• India has employed a comprehensive five-pronged strategy: Mission mode MDA, Morbidity Management and Disability Prevention (MMDP), Vector control (Surveillance and Management), High-level advocacy, and Innovative approaches for the elimination of LF.

Present Scenario

• 138 (40%) of the total endemic districts stopped Mass Drug Administration and cleared Transmission Assessment Survey (TAS 1), 159 districts of 13 states reported Mf >1 conducting Annual Mass Drug Administration and 41 districts are in various stages of Pre TAS/TAS, 5 districts failed Pre TAS (>1 Mf rate in 8 blocks) and 2 districts of Assam postponed MDA to 2025.
• Till 2023, 6.19 lakh cases of lymphoedema and 1.27 lakh cases of hydrocele were reported from all the endemic districts.
• India on eradicating lymphatic filariasis
• india's efforts to eliminate lymphatic filariasis (LF) have seen significant progress with the launch of the Enhanced Strategy for LF Elimination by 2027. 
• This strategy includes the mission mode Annual Mass Drug Administration (MDA) campaign, conducted biannually on 10th February and 10th August alongside National Deworming Day (NDD).
• In 2023, MDA was conducted in two phases, and reached 82% coverage nationally across 170 districts in 12 states, emphasizing Directly Observed Consumption. 
• In 2024, the first phase of the MDA campaign was conducted in 96 districts across 11 states and reported national coverage of 95% against the eligible population.

For a successful execution of the MDA campaign, it is essential to provide information to all the households about the importance of the anti-filaria drug consumption to attain the targeted drug compliance of more than 90% against the eligible population. As part of the second phase of the MDA campaign on 10th August 2024, 63 districts (38 triple drug & 25 double drug), and 771 blocks across 6 states are conducting the MDA campaign.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!